
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : GB-0895
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Investigate GB-0895 in Adults with Mild to Moderate Asthma or COPD
Details : GB-0895 is a Antibody drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 12, 2025
Lead Product(s) : GB-0895
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : GB-0669
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Investigate Safety, Tolerability & PK of GB-0669 in Healthy Adults
Details : GB-0669 is a Other Large Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 03, 2025
Lead Product(s) : GB-0669
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : GB-7624
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GB-7624 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Dermatitis, Atopic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 10, 2025
Lead Product(s) : GB-7624
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $1,065.0 million
Deal Type : Collaboration
Novartis Inks $1B-plus Biobucks Deal with Flagship's Generate
Details : The collaboration leverages Generate’s proprietary generative AI platform to create potentially first- and best-in-class molecules through AI-based optimization and de novo generation.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $65.0 million
September 24, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $1,065.0 million
Deal Type : Collaboration

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Roswell Park Comprehensive Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to discover and develop chimeric antigen receptor (CAR) T-cell therapies, and armoring technologies, for up to three oncology targets, including in ovarian cancer and other solid tumors.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 01, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Roswell Park Comprehensive Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : GB-0669
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Amgen Inc
Deal Size : $273.0 million
Deal Type : Series C Financing
Details : The financing will be used to advance company's Generative AI pipeline of preclinical and clinical protein therapeutics, including GB-0669, a monoclonal antibody targeting a highly conserved region of the spike protein, in SARS-CoV-2.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 14, 2023
Lead Product(s) : GB-0669
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Amgen Inc
Deal Size : $273.0 million
Deal Type : Series C Financing

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : The University of Texas MD Anderson Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to jointly discover and co-develop protein therapeutics for up to 5 oncology targets in advanced cancers, including small-cell and NSCLC. The agreement combines Generate:Biomedicines’ The Generate Platform with MD Anderson’s cl...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 27, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : The University of Texas MD Anderson Cancer Center
Deal Size : Undisclosed
Deal Type : Collaboration

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Discovery Platform
Sponsor : Amgen Inc
Deal Size : $1,900.0 million
Deal Type : Collaboration
Details : Generate Biomedicine's integrated in silico design and wet lab capabilities combined with Amgen to harness its machine-learning-enabled technology to discover and develop protein therapeutics for five clinical targets across a range of therapeutic areas ...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $50.0 million
January 06, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Discovery Platform
Sponsor : Amgen Inc
Deal Size : $1,900.0 million
Deal Type : Collaboration

 Reset All
Reset All